Impact of weight on PFS in the RICOVER-60 trial. In patients with a body weight within the lower quartile of the respective sex (≤ 60 kg and ≤ 73 kg for females and males, respectively), the addition of 8 cycles of rituximab to CHOP-14 resulted in a significant (P = .023) improvement of PFS (A). In contrast, in patients with a body weight within the upper quartile of the respective sex (> 77 kg and > 89 kg in females and males, respectively), who have a faster rituximab clearance, this improvement was only minor (P = .284; B). Black curves indicate CHOP-14 without rituximab; gray curves, CHOP-14 with 8 applications of rituximab every 2 weeks.